Top

Published in:

01-02-2019 | Observational Research

Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

Authors: Elena Generali, Greta Carrara, Marinos Kallikourdis, Gianluigi Condorelli, Alessandra Bortoluzzi, Carlo A. Scirè, Carlo Selmi

Published in: Rheumatology International | Issue 2/2019

Abstract

To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95% CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95% CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.

van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, Stehouwer CD, Spijkerman AM, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Smulders YM, Dijkmans BA, Nurmohamed MT (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68(9):1395–1400. https://doi.org/10.1136/ard.2008.094151 CrossRefPubMed

Pinheiro FA, Souza DC, Sato EI (2015) A study of multiple causes of death in rheumatoid arthritis. J Rheumatol. https://doi.org/10.3899/jrheum.150166 CrossRefPubMed

Schau T, Gottwald M, Arbach O, Seifert M, Schopp M, Neuss M, Butter C, Zanker M (2015) Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol 42(11):2029–2037. https://doi.org/10.3899/jrheum.141647 CrossRefPubMed

Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055–2059CrossRefPubMed

Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323(4):236–241. https://doi.org/10.1056/NEJM199007263230405 CrossRefPubMed

Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977. https://doi.org/10.1136/annrheumdis-2016-210715 CrossRef

Javed Q, Murtaza I (2013) Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ 22(5):323–327. https://doi.org/10.1016/j.hlc.2012.12.002 CrossRefPubMed

Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR (2013) Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis 72(11):1813–1818. https://doi.org/10.1136/annrheumdis-2012-202136 CrossRefPubMed

Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 51(suppl 5):38-47. https://doi.org/10.1093/rheumatology/kes114 CrossRef

10.

Generali E, Carrara G, Selmi C, Verstappen S, Zambon A, Bortoluzzi A, Scirè C (2018) Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. Clin Exp Rheumatol 36(2):310–313PubMed

11.

Kallikourdis M, Martini E, Carullo P, Sardi C, Roselli G, Greco CM, Vignali D, Riva F, Ormbostad Berre AM, Stolen TO, Fumero A, Faggian G, Di Pasquale E, Elia L, Rumio C, Catalucci D, Papait R, Condorelli G (2017) T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun 8:14680. https://doi.org/10.1038/ncomms14680 CrossRefPubMedPubMedCentral

12.

Carrara G, Scire CA, Zambon A, Cimmino MA, Cerra C, Caprioli M, Cagnotto G, Nicotra F, Arfe A, Migliazza S, Corrao G, Minisola G, Montecucco C (2015) A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology. BMJ Open 5(1):e006029. https://doi.org/10.1136/bmjopen-2014-006029 CrossRefPubMedPubMedCentral

13.

Corrao G, Ghirardi A, Ibrahim B, Merlino L, Maggioni AP (2014) Burden of new hospitalization for heart failure: a population-based investigation from Italy. Eur J Heart Fail 16(7):729–736. https://doi.org/10.1002/ejhf.105 CrossRefPubMed

14.

Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velazquez F, Aronovitz M, Kapur NK, Karas RH, Blanton RM, Alcaide P (2015) Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail 8(4):776–787. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002225 CrossRefPubMedPubMedCentral

15.

Selmi C, Ceribelli A, Naguwa SM, Cantarini L, Shoenfeld Y (2015) Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf 14(3):389–399. https://doi.org/10.1517/14740338.2015.993605 CrossRefPubMed

16.

Silvagni E, Bortoluzzi A, Carrara G, Zanetti A, Govoni M, Scire CA (2018) Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. BMJ Open 8(9):e021447. https://doi.org/10.1136/bmjopen-2017-021447 CrossRefPubMedPubMedCentral

17.

Carrara G, Bortoluzzi A, Sakellariou G, Silvagni E, Zanetti A, Govoni M, Scire CA (2018) Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clin Exp Rheumatol [Epub ahead of print]

18.

Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scire CA (2017) Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open 3(2):e000523. https://doi.org/10.1136/rmdopen-2017-000523 CrossRefPubMedPubMedCentral

19.

Buttgereit JWJB F (2016) Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies. Rheumatology 55(suppl 2):ii3–ii5. https://doi.org/10.1093/rheumatology/kew344 CrossRefPubMed

20.

Ajeganova S, Svensson B, Hafstrom I, Group BS (2014) Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open 4(4):e004259. https://doi.org/10.1136/bmjopen-2013-004259 CrossRefPubMedPubMedCentral

Title: Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept
Authors: Elena Generali
Greta Carrara
Marinos Kallikourdis
Gianluigi Condorelli
Alessandra Bortoluzzi
Carlo A. Scirè
Carlo Selmi
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 2/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-018-4196-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Tuberculosis and Takayasu arteritis: case-based review

Similarity of autoimmune diseases based on the profile of immune complex antigens

Evaluation of six-minute walk test in juvenile systemic sclerosis

Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature

Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review

Raynaud’s phenomenon in Northern Sweden: a population-based nested case–control study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page